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Deregulation of microRNAs expression occurs in stages of multistep
hepatocarcinogenesis: Why is it different?
deregulated during the multistep hepatocarcinogenesis. While
other miRNAs’ expression changes seldom reached statistically
signiﬁcant levels among non-tumorous livers, dysplastic nodules
and small HCC, after Bonferroni correction for multiple compari-
son tests [7]. This conclusion was quite different from other study
results. Pineau et al. concluded that among the miRNAs present in
the progression signature, miR-221 was capable of stimulating
tumor growth in vivo possibly through p27 and/or DDIT4 down-
regulation [8]. The ﬁndings of Kutay et al. suggested that miR-122
downregulation was associated with hepatocarcinogenesis and
could be a potential biomarker for liver cancer [9]. Connolly
et al. initial analysis of cirrhotic livers suggested that upregula-
tion of miR-17-92 and miR-21 occurred in pre-cancerous stages
of liver disease [10]. Then, which conclusion is more convincing?
And what makes them into controversies?
JOURNAL OF HEPATOLOGYTo the Editor:
HBV is a major cause of acute and chronic liver infection, and can
lead to hepatitis, cirrhosis, and hepatocellular carcinoma (HCC)
[1], which is the ﬁfth most common cancer and the third leading
cause of cancer death worldwide. More than 80% of HCC patients
are in developing countries, especially in Southeast Asia and sub-
Saharan Africa. However, the incidence of HCC has been rising in
Western countries in recent years [2]. The current standard of
care and therapy for patients with advanced HCC are not satisfac-
tory. Surgical resection or liver transplantation remains the most
effective treatment options for HCC, but few patients are fortu-
nate to get the treatment, for all kinds of reasons. Therefore,
the analysis of the molecular mechanisms of oncogenesis is badly
needed to uncover novel targets for speciﬁc systemic therapy and
to discover novel biomarkers for early diagnosis of HCC.MicroRNAs (miRNAs), which are endogenous, small non-cod-
ing RNAs consisting of 20–25 nucleotides, have been shown to
play important roles in various cellular and physiological pro-
cesses, including cellular development, apoptosis, proliferation,
and differentiation [3,4]. Typically, they modulate gene expres-
sion by regulating the mRNA at a posttranscriptional stage,
base-pairing with sequences in the 30-untranslated region [3,5].
There are currently 940 identiﬁable humanmiRNAs (The miRBase
Sequence Database-Release ver. 15.0), which can recognize hun-
dreds of target genes with incomplete complementarity and over
one third of human genes appear to be conserved miRNA targets
[6]. Recent evidence clearly shows that deregulation of miRNAs
may contribute to aberrant activation of oncogenes and inactiva-
tion of tumor suppressor genes in human carcinogenesis. Several
miRNAs have been linked to the initiation and progression of
human cancers, including HBV-associated HCC [7–10]. Thus, great
efforts have been put on miRNA mimetics and anti-sense miRNA
as potential therapeutics for hepatocellular carcinoma, due to
their stability and predominant uptake by the liver.
In the study by Gao et al. [7], a panel of seven miRNAs (miR-
10b, miR-21, miR-122, miR-145, miR-199b, miR-221, and miR-
224) was selected to examine miRNA deregulation during early
stages of hepatocarcinogenesis. Among these miRNAs, only
miR-145, miR-199b, and miR-224 were found to be signiﬁcantly
Despite the difference in the methods used by the research-
ers, the development of hepatocellular carcinoma in individuals
with chronic hepatitis B is a multistage, multifactorial process
including the interaction between host and environmental
factors [11]. Risk factors for chronic HBV-related hepatocellular
carcinoma include HBV DNA level, sex, age, cigarette smoking,
alcohol consumption, chemical carcinogens, hormonal factors,
and genetic susceptibility [12]. In a previous study, Zhang
et al. [13] demonstrated that perturbations of miRNA expression
during HBV infection were signiﬁcantly correlated with those in
HCC, and that aberrant expression of miR-199a, miR-199a⁄,
miR-200a, and miR-200b was associated with liver ﬁbrosis
progression. In addition, the work by Liu et al. [14] suggested
that microRNA-18a prevented estrogen receptor expression,
promoting proliferation of hepatocellular carcinoma cells, which
could be a mechanism explaining the sex disparity observed in
HCC. However, the relationship between miRNA expression and
other risk factors for chronic HBV-related HCC remains elusive.
In the past studies, scientists paid most of their attention on
the miRNA expression changes during the process of HCC, with-
out taking other risk factors for chronic HBV-related HCC into
consideration. Even though more and more miRNAs are being
reported to be frequently deregulated in human cancers and
may play a role in liver carcinogenesis, it is difﬁcult to judge
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which result is more convincing. Altered miRNA expression has
been clearly linked to liver cancer, but the molecular mecha-
nisms by which miRNA modulates hepatocarcinogenesis are still
unknown. The reasons for their controversial study results are
complex; we think lack of consideration of risk factors for
chronic HBV-related HCC in these studies may be one of the
key reasons.
In summary, well designed and systematic studies are still
needed to clarify the molecular mechanism that leads to deregu-
lation of miRNA expression in HBV-associated multistep hepato-
carcinogenesis. Incorporating HBV DNA level, sex, age, cigarette
smoking, alcohol consumption, chemical carcinogens, hormonal
factors, and genetic susceptibility when investigating the rela-
tionship between deregulation of miRNA expression and HCC
may be helpful in resolving the controversies.
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Reply to: ‘‘Deregulation of microRNAs expression occurs in stages
of multistep hepatocarcinogenesis: Why is it different?’’
To the Editor:
Yin et al. drew attention to the differences between the ﬁndings
on miR-221, miR-21 and miR-122 deregulation in hepatocarcino-
genesis reported in our recent study [1] and others [2–4]. Yin
et al. further speculated that the inconsistence of the ﬁndings
among these reports might be due to different risk factors for
HCC and called for further investigations on this subject.
In our article, we reported ﬁndings on the expression levels of
seven cancer-related miRNAs in a series of chronic hepatitis/cir-
rhotic livers, dysplastic nodules (DNs) and small HCC samples.
We found that miR-145, miR-199b and miR-224 were signiﬁ-
cantly deregulated in early stages of hepatocarcinogenesis (DN
and small HCCs) when compared to the corresponding non-
tumorous livers. The evidence for miR-21, miR-221, miR-10b
and miR-122 deregulation was less clear and the data did not
reach the stringent statistical threshold employed for that study
(p <0.001 for one-way ANOVA and post tests with Bonferroni cor-
rection for multiple comparisons). However, we have to empha-
size that our analysis mainly focused on the early stages of
hepatocarcinogenesis and whether a miRNA was deregulated in
DNs and small HCCs. Although our ﬁndings failed to demonstrate
a statistically signiﬁcant deregulation of miR-21, miR-221, miR-
10b, and miR-122 in early stages of hepatocarcinogenesis, our
ﬁndings in no way excluded the possibility of deregulation of
these miRNAs in later stages of HCC. In fact, we found that
miR-221 and miR-122 were signiﬁcantly deregulated in early
stages of HCCs when compared to the non-tumorous liver sam-
ples (p <0.001, post test with Bonferroni correction, Supplemen-
tary Fig. 1). An increasing trend was also observed with miR-21
when small HCCs were compared with the non-tumorous livers.
These ﬁndings were actually in line with those of the previous
reports [2–4].
In principle, we agree with Yin et al. that risk factors may
affect the miRNA expression pattern in HCCs. In our study, we
focused on the miRNA deregulation in HBV-associated HCC [1].
Indeed, the HCC samples used in the above-mentioned studies
had substantially different etiological backgrounds when com-
pared to our sample cohort. Kutay et al. mainly focused on pre-
malignant nodules and HCC samples obtained from foliate and
methyl-deﬁcient (FMD) diet-fed Fisher 334 rats, while the risk
factors of the three human HCC samples in their study were
not described [3]. In the study of Pineau et al. the HCC samples
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